sti-6129
mAbexperimental
Clinical trial activity
6 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2020 (NCT04316442)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Lymphocyte differentiation antigen CD38Supplementation
CD38 supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05692908 | Phase 1 | Sep 30, 2023 | Sorrento Therapeutics, Inc. |
| NCT05584709 | Phase 1 | Mar 31, 2023 | Sorrento Therapeutics, Inc. |
| NCT05519527 | Phase 1 | Feb 28, 2023 | University of Texas at Houston |
| NCT05308225 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2022 | Columbia University, New York University, Sorrento Therapeutics, Inc. |
| NCT05565807 | Phase 1/Phase 2 (Phase 2) | Dec 23, 2022 | Acea Bio, Sun Yat-Sen University, Zhejiang University |
| NCT04316442 | Phase 1 | Aug 1, 2020 | Columbia University, Sorrento Therapeutics, Inc. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sorrento Therapeutics, Inc. | For profit | 4 | 4 | 2 | 2020 |
| Columbia University | Academic/Hospital | 2 | 0 | 2 | 2020 |
| Acea Bio | For profit | 1 | 1 | 1 | 2022 |
| New York University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Zhejiang University | Academic/Hospital | 1 | 0 | 1 | 2022 |
7 organizations
Page 1 / 1